About Polydex
As far back as 1969, we have been engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry as well as the manufacture and marketing of biotechnology-based products for human pharmaceutical markets. Business is conducted through our wholly-owned subsidiaries, Dextran Products in Canada and Chemdex in the United States.
Common Shares
Shares Issued & Outstanding - 3,425,978
An OTC Pink Foreign Issuer - POLXF
Electronically Quoted with OTC Markets
Fiscal Year End - January 31st
Currently a SEC non-reporting issuer
Recent News
December 15, 2020
Polydex Pharmaceuticals Ltd.
Issues Third Quarter Financial Results
Company remains profitable with strong balance sheet and cash position.